VITX (923144) News!! Neues Aids Medikament!!!!! - 500 Beiträge pro Seite
eröffnet am 14.07.04 09:26:40 von
neuester Beitrag 14.07.04 10:10:06 von
neuester Beitrag 14.07.04 10:10:06 von
Beiträge: 4
ID: 880.168
ID: 880.168
Aufrufe heute: 0
Gesamt: 300
Gesamt: 300
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 30 Minuten | 4448 | |
| vor 36 Minuten | 2554 | |
| vor 1 Stunde | 2243 | |
| vor 33 Minuten | 2121 | |
| vor 31 Minuten | 1103 | |
| vor 1 Stunde | 1072 | |
| vor 40 Minuten | 904 | |
| heute 07:24 | 844 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.025,23 | +0,12 | 164 | |||
| 2. | 6. | 7,5700 | -9,88 | 55 | |||
| 3. | 2. | 0,1855 | 0,00 | 42 | |||
| 4. | 44. | 483,90 | +1,02 | 33 | |||
| 5. | 15. | 10,400 | 0,00 | 29 | |||
| 6. | 4. | 165,56 | -0,42 | 27 | |||
| 7. | 16. | 18,000 | +2,56 | 26 | |||
| 8. | Neu! | 26,91 | -0,46 | 25 |
Feedback
Reuters
U.S. biotech Panacos unveils new kind of AIDS drug
Wednesday July 14, 3:00 am ET
BANGKOK, July 14 (Reuters) - A new kind of AIDS drug, which interrupts the last of the six stages in the life-cycle of HIV, has cleared the initial hurdle of clinical development, its developer said on Wednesday.
ADVERTISEMENT
Privately held U.S. biotech firm Panacos Pharmaceuticals told scientists at the 15th International AIDS Conference the oral maturation inhibitor was well tolerated at various doses in a Phase I study and reached required levels in patients` blood.
The company now plans to start intermediate Phase II studies, which will look at exactly how well the drug fights the human immunodeficiency virus (HIV) that causes AIDS. Panacos believes it will be suitable for taking as a once-daily pill.
"If all goes well, we would hopefully be able to file for regulatory approval sometime early in 2007," Dr Carl Wild, Panacos` Chief Science Officer, told Reuters.
The product, known by the codename PA-457, is one of a number of new anti-AIDS drugs researchers announced at the Bangkok meeting and which may offer a lifeline for patients who have developed resistance to existing treatments.
"It targets a novel point in virus replication, making it effective against viruses that are currently resistant to other treatments," Wild said.
PA-457 has also been shown to be an effective inhibitor of HIV replication, both in test-tube and animal tests, with a level of potency similar to the established anti-AIDS drug lamivudine.
Last month, Panacos Pharmaceuticals agreed to be acquired by V.I. Technologies (NasdaqNM:VITX - News), a Nasdaq-listed company focused on anti-infective drugs.
U.S. biotech Panacos unveils new kind of AIDS drug
Wednesday July 14, 3:00 am ET
BANGKOK, July 14 (Reuters) - A new kind of AIDS drug, which interrupts the last of the six stages in the life-cycle of HIV, has cleared the initial hurdle of clinical development, its developer said on Wednesday.
ADVERTISEMENT
Privately held U.S. biotech firm Panacos Pharmaceuticals told scientists at the 15th International AIDS Conference the oral maturation inhibitor was well tolerated at various doses in a Phase I study and reached required levels in patients` blood.
The company now plans to start intermediate Phase II studies, which will look at exactly how well the drug fights the human immunodeficiency virus (HIV) that causes AIDS. Panacos believes it will be suitable for taking as a once-daily pill.
"If all goes well, we would hopefully be able to file for regulatory approval sometime early in 2007," Dr Carl Wild, Panacos` Chief Science Officer, told Reuters.
The product, known by the codename PA-457, is one of a number of new anti-AIDS drugs researchers announced at the Bangkok meeting and which may offer a lifeline for patients who have developed resistance to existing treatments.
"It targets a novel point in virus replication, making it effective against viruses that are currently resistant to other treatments," Wild said.
PA-457 has also been shown to be an effective inhibitor of HIV replication, both in test-tube and animal tests, with a level of potency similar to the established anti-AIDS drug lamivudine.
Last month, Panacos Pharmaceuticals agreed to be acquired by V.I. Technologies (NasdaqNM:VITX - News), a Nasdaq-listed company focused on anti-infective drugs.
gibst dazu auch eine WKN?? Vielleicht von der VI Tech?
Maria.
Maria.
Sorry, war etwas unübersichtlich!!!
WKN 923144
Gruß
gino
WKN 923144
Gruß
gino
SEHR INTERESSANT:
http://biz.yahoo.com/e/040510/vitx10-q.html
"At March 27, 2004, we had working capital of $11.6 million, including cash of $13.4 million, in comparison with working capital of $6.8 million, including cash of $4.3 million at the prior year end."
Die haben genug Barreserven um weiterhin erfolgreich zu arbeiten. Dazu zählt dann wohl auch die Übernahme von Panacos und deren erfolgreiche Arbeit.
Maria
http://biz.yahoo.com/e/040510/vitx10-q.html
"At March 27, 2004, we had working capital of $11.6 million, including cash of $13.4 million, in comparison with working capital of $6.8 million, including cash of $4.3 million at the prior year end."
Die haben genug Barreserven um weiterhin erfolgreich zu arbeiten. Dazu zählt dann wohl auch die Übernahme von Panacos und deren erfolgreiche Arbeit.
Maria
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 164 | ||
| 55 | ||
| 42 | ||
| 33 | ||
| 29 | ||
| 27 | ||
| 26 | ||
| 25 | ||
| 22 | ||
| 21 |
| Wertpapier | Beiträge | |
|---|---|---|
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 14 | ||
| 13 | ||
| 10 | ||
| 10 | ||
| 10 |
